FDA clears AliveCor's mobile 6-lead ECG

With a third electrode on the bottom of the device, the pose forms a triangle of ECG leads across the three limbs, placing the heart at the center. (AliveCor)

While other on-the-go electrocardiograms may only observe the heart’s electrical signals from a single angle, AliveCor has moved ahead to secure an FDA clearance for its personal device offering six leads, providing more detailed views into heartbeats and arrhythmias.  

The former Fierce 15 winner’s KardiaMobile 6L looks and acts similar to its predecessor, with two thumb-pad electrodes on the top of the card-sized ECG. The upgrade comes with the addition of a third electrode on the bottom, to be held on top of the left knee or ankle.

In this pose, the device forms what’s known as Einthoven's triangle, named for the inventor of the ECG, made up of leads from three limbs and the heart at the center. The company said this allows the user to detect a broader range of heart conditions when pairing the device with their smartphone.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"KardiaMobile 6L is the most clinically valuable personal ECG ever created, and another significant step in AliveCor's march to making heart care more convenient, more accessible, and less expensive than ever before," CEO Ira Bahr said in a statement.

RELATED: Mayo Clinic and AliveCor use AI to detect ‘invisible’ heart condition

The device is cleared to detect atrial fibrillation, bradycardia and tachycardia, as well as a normal heart rhythm, over a period of 30 seconds. The company is currently taking preorders for the device and plans to make it available in June.

The FDA green light is the company’s third in the past three months, following additional clearances for its two-electrode device to spot bradycardia and tachycardia, two of the most common irregular heartbeats.

RELATED: Apple, J&J to put the Apple Watch’s ECG through large-scale clinical testing

Additionally, AliveCor recently signed a partnership in China to supply its device to the country. The company estimates about 10 million people there are living with atrial fibrillation, among 300 million with heart disease.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.